Caitlin Duffy joined Interactive Brokers in 2009. In her role as Equity Options Analyst, Caitlin provides daily market commentary; highlighting various options trades, trading patterns and strategies of interest. Through Interactive Broker's webinar program, Ms. Duffy presents a number of educational, options-related events describing the theoretical pricing of options, the option Greeks as well as options strategies.
Visit: Interactive Brokers Group (http://www.ibkr.com)
I am an Senior Biotech Analyst with Zacks Investment Research, Inc. I joined Zacks in February 2014.
Prior to joining Zacks, I was an NRSA Postdoctoral Fellow working in a cancer genetics laboratory.
I received my PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. I also have my BS and MS in Biochemistry from Virginia Tech.
Editor for The Biotech Forum, the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade.
Please go to biotechforumsa.com for more on the Biotech Forum service available through SeekingAlpha. For Free Investment Reports on a variety of topics go to bretjenseninvests.com
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
Honest (and sometimes too analytical and verbose) insights from a guy that has done pretty well investing and managing money – but only after getting annihilated along the way several times.
Founder of Old School Value (www.oldschoolvalue.com).
Fundamental Stock Analyzer & Valuation Tool for Value Investors to Save Time & Make Money
- Are you spending a lot of time manually gathering and inputting data into spreadsheets?
- Are you finding it difficult to keep up to date with fundamental company valuations?
- Do you need a way to quickly check whether a company is worth investigating?
- Do you want to know what a company is worth quickly?
The Old School Value Stock Analysis Software is a fundamental analysis and valuation tool that works for you.
Save hours each day by automatically retrieving and crunching the financials for thousands of companies.
Keep up to date easily and find more opportunities by analyzing companies faster and use the 5 valuation models to cross check whether the stock price is an attractive entry price or time to get out.
Learn more at http://try.oldschoolvalue.com/stock-analyzer/
Private full time investor since 1994, graduated in medicine, with interests in art and philosophy coming from Italy and living in Hungary, dealer in old masters painting until 1996. Overcame 2 big market crashes in 2002 and 2008. The strategy is to divide the assets in 2 categories: the first one invested in long term holdings and and the second for short term investments and trading.
I hold a PhD in Electrical Engineering (Control Theory) from Stanford University and a Masters Degree in Engineering-Economic Systems (now called Management Science and Engineering at Stanford).
I have been fascinated by the stock market since I was 14 (that is 37 years ago at writing). It has always struck me as the place to be.
In the last 10+ years I moved from what I would call the "herd mentality" to a more educated process. In particular, my years as a Principal Software Engineer in a derivatives software development company, interacting closely with Financial Engineers, showed me clearly the simple science behind this: "Mean Reversion is All We Know about the Game!"
Bay Area Biotech is a group of self-organized life science graduate/medical/business students and postdoctoral scholars who are interested in utilizing our scientific training to evaluate biotechnologies and identify investment opportunities. Opinions published here are those of the authors.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
Private Investor with 10 years of biotech trading experience.
I use basic disciplined research approach to discover new investment ideas. Biotech sector is full of violent stock moves and trial failures. On one hand it requires traders to be quick on their feet and on the other hand it forces investors to have a great deal of patience.
I enjoy the challenge of mining for hidden gems, because its 10 times as hard to do that than predicting failures. Failure is the norm in biotech, I look for exception to the norm!
Sheff can be followed at twitter.com/SheffStation. He is an investor & trader of big board, small cap, and biotech stocks. He uses fundamental analysis and extensive DD (due diligence) to trade. Over the years, he has learned a great deal about how the FDA works and what they look for when considering a drug for approval. His success record in stock picking and many yrs in the biotech & pharmaceutical industry has helped him in his analysis of biotech & pharma stocks. His goal is to find undervalued companies and help the individual investor by discussing clinical data that could be relevant in how the FDA will make a decision for a drug or clinical data.
Do your own due diligence and never buy a stock based on what Sheff discusses or says.
Sheff is is not a licensed broker or financial advisor of any kind nor is he qualified to act as an investment advisor. His articles are written for discussion purposes only. None of the information written about by Sheff is to be construed as financial or investment advice. The information shared is not to be construed as an offer to buy or sell any security. Sheff works diligently to avoid misstatements of fact, but advises all investors to consult a licensed profession prior to making an investment in any stock he discusses. The information on this site is gathered from sources available to the public
Sheff's hobbies are reading, family, and helping people. I enjoy the work I do as a Chemo Specialist in many cancer centers and the volunteer work as a member with a Cancer Organization where I raise money for awareness & other programs vital for children with different forms of cancer.
I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has been researching the treatment options for many cancers and prevention of their recurrence. Additional recent research has been in the stem cell field, an exciting field in its infancy but now becoming a teenager! My ongoing goal for investors is attempting to find under-the-radar or oversold pharmaceuticals or biotechs for investment potential.